Login to Your Account

BIO 2012

Uptake of Biosimilars in Europe is Slow, Rocky

By Nuala Moran
Staff Writer

Wednesday, June 20, 2012
BOSTON – Mind the gap. It's not enough to chart a regulatory pathway and see biosimilar products through to approval; there remain problems with promoting uptake and delivering the promised cost savings to payers, as experience in Europe illustrates.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription